Vanessa Anton Muñoz

Ms. Vanessa Anton Muñoz

Lima, Universidad Nacional Mayor de San Marcos, Lima, Peru
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
M. Nuria Peralta MorenoM. Nuria Peralta Moreno
M. Nuria Peralta Moreno
VMVanessa Anton Muñoz
Vanessa Anton Muñoz
DADavid Ortega Alarcon
David Ortega Alarcon
AJAna Jimenez-Alesanco
Ana Jimenez-Alesanco
SVSonia Vega
Sonia Vega
JRJaime Rubio-Martinez
Jaime Rubio-Martinez
Over 750 million cases of COVID-19, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), have been reported since the onset of the global outbreak. The need for effective treatments has spurred intensive research for therapeutic agents based on pharmaceutical repositioning or natural products. In light of prior studies asserting the bioactivity of natural compounds of the autochthonous Peruvian flora, the present study focuses on the identification SARS-CoV-2 Mpro main protease dimer inhibitors. To this end, a target-based virtual screening was performed over a representative set of Peruvian flora-derived natural compounds. The best poses obtained from the ensemble molecular docking process were selected. These structures were subjected to extensive molecular dynamics steps for the computation of binding free energies along the trajectory and evaluation of the stability of the complexes. The compounds exhibiting the best free energy behaviors were selected for in vitro testing, confirming the inhibitory activity of Hyperoside against Mpro, with a Ki value lower than 20 µM, presumably through allosteric modulation.